Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119371) titled 'Evaluation of the Efficacy and safety of Vericiguat therapy in Patients with Cardiac Amyloidosis: A Randomized, Double-Blind, Placebo-Controlled study' on Feb. 26.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Fuwai Hospital, Chinese Academy of Medical Sciences
Condition:
Cardiac Amyloidosis
Intervention:
Experimental group:Administer vericiguat (starting at 5 mg/day and titrating to 10 mg/day or the maximum tolerated dose).
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-03
Target Sample Size: Experimental group:100;Placebo control group:1...